SD-101

Phase 2Small molecule

Merck & Co.

SD-101 is one of 225 small molecule programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

224

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Chronic HepatitisActive, not recruiting

Uveal MelanomaActive, not recruiting

Metastatic Prostate CancerActive, not recruiting

Pancreatic AdenocarcinomaActive, not recruiting

Head and Neck Squamous Cell CarcinomaActive, not recruiting

LymphomaPhase 1

Active, not recruiting

Chronic HepatitisPhase 1

Active, not recruiting

Uveal MelanomaPhase 1

Active, not recruiting

Metastatic Prostate CancerPhase 2

Active, not recruiting

Pancreatic AdenocarcinomaPhase 1

Active, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

SD-101

Merck & Co.

Phase 2

3 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Oncaspar

SServier

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Tafasitamab

Incyte

Preclinical

7 6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—10

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Tremelimumab

NCT06710223

Q4 2027

Phase 1Active, not recruiting

Pancreatic Adenocarcinoma

NCT05607953

Clinical

Trials by Indication[1]

Lymphoma3 trials

Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)

Terminated·RRobert Lowsky·Phase 1·NCT01745354·6 enrolled

UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma

Completed·UUniversity of California, Davis·Phase 1/2·NCT03322384·20 enrolled

Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma

Terminated·DDynavax Technologies Corporation·Phase 1/2·NCT02266147·29 enrolled

Metastatic Prostate Cancer1 trial

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Completed·DDavid Oh·Phase 2·NCT03007732·23 enrolled

Pancreatic Adenocarcinoma1 trial

Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

Active, not recruiting·TTriSalus Life Sciences, Inc.·Phase 1·NCT05607953·60 enrolled

Tremelimumab1 trial

Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab

Recruiting·UUniversity of California, San Diego·Phase 1·NCT06710223·20 enrolled

Advanced Malignancies1 trial

Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT02731742·14 enrolled

6 more indications

Uveal Melanoma1 trial

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Terminated·TTriSalus Life Sciences, Inc.·Phase 1·NCT04935229·67 enrolled

Tics1 trial

Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males

Completed·DDynavax Technologies Corporation·Phase 1·NCT00599001·26 enrolled

Chronic Hepatitis1 trial

Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

Completed·DDynavax Technologies Corporation·Phase 1·NCT00823862·34 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Terminated·DDynavax Technologies Corporation·Phase 1/2·NCT02521870·241 enrolled

Tumors1 trial

Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

Terminated·TTriSalus Life Sciences, Inc.·Phase 1/2·NCT05220722·23 enrolled

Intratumoral Injection1 trial

A Phase I/II Study of Intratumoral Injection of SD-101

Completed·RRobert Lowsky·Phase 1/2·NCT02254772·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for SD-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SD-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SD-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

SD-101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Trials by Indication[1]

Lymphoma3 trials

Metastatic Prostate Cancer1 trial

Pancreatic Adenocarcinoma1 trial

Tremelimumab1 trial

Advanced Malignancies1 trial

Uveal Melanoma1 trial

Tics1 trial

Chronic Hepatitis1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Tumors1 trial

Intratumoral Injection1 trial

References

Drug Info

Quick Facts

Related News